Cancer Survivors Program
Cancer Survivors Program: Effectiveness of Monitoring Adverse Events After Completion of Curative Treatment for Breast and Prostate Cancer
Masaryk Memorial Cancer Institute
200 participants
May 5, 2025
INTERVENTIONAL
Conditions
Summary
The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.
Eligibility
Inclusion Criteria7
- The patient understands the information provided and agrees to participate in the study.
- Age 18 years or older.
- Histologically confirmed invasive breast cancer or invasive prostate cancer.
- Completion of the acute phase of curative oncological therapy:
- for breast cancer: curative surgery performed + completed neoadjuvant/adjuvant chemotherapy and completed adjuvant radiotherapy, if indicated
- for prostate cancer: completed radiotherapy with curative intent or radical prostatectomy performed (open, laparoscopic, robotic) or completed adjuvant radiotherapy after prostatectomy
- The patient is available for follow-up within 12 months of enrollment in the study.
Exclusion Criteria5
- Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4/6i, PARPi, T-DM1), (iii) adjuvant immunotherapy)
- Neoadjuvant/adjuvant therapy did not include chemotherapy (breast cancer).
- Recurrence of cancer
- Metastatic disease
- History of other primary malignancy (except for non-melanoma skin cancer)
Interventions
Based on the Questionnaire for the Assessment of Difficulties after the completion of cancer treatment, the attending physician will assess the need for intervention and respond appropriately to the reported problems. Intervention is assessed as education by the physician, the use of medication, or referral of the patient to a specialized outpatient clinic.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07253987